{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T07:49:42Z","timestamp":1778658582174,"version":"3.51.4"},"reference-count":50,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T00:00:00Z","timestamp":1714435200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Roswell Park Comprehensive Cancer Center"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>Background: KEYNOTE-522 resulted in FDA approval of the immune checkpoint inhibitor pembrolizumab in combination with neoadjuvant chemotherapy for patients with early-stage, high-risk, triple-negative breast cancer (TNBC). Unfortunately, pembrolizumab is associated with several immune-related adverse events (irAEs). We aimed to identify potential tumor microenvironment (TME) biomarkers which could predict patients who may attain pathological complete response (pCR) with chemotherapy alone and be spared the use of anti-PD-1 immunotherapy. Methods: Comprehensive immune profiling, including RNA-seq gene expression assessment of 395 immune genes, was performed on matched FFPE tumor samples from 22 stage I-III TNBC patients (14 patients treated with neoadjuvant chemotherapy alone (NAC) and 8 treated with neoadjuvant chemotherapy combined with pembrolizumab (NAC+I)). Results: Differential gene expression analysis revealed that in the NAC group, IL12B and IL13 were both significantly associated with pCR. In the NAC+I group, LCK and TP63 were significantly associated with pCR. Patients in both treatment groups exhibiting pCR tended to have greater tumor inflammation than non-pCR patients. In the NAC+I group, patients with pCR tended to have greater cell proliferation and higher PD-L1 expression, while in the NAC group, patients with pCR tended to have lower cancer testis antigen expression. Additionally, the NAC+I group trended toward a lower relative dose intensity averaged across all chemotherapy drugs, suggesting that more dose reductions or treatment delays occurred in the NAC+I group than the NAC group. Conclusions: A comprehensive understanding of immunologic factors could potentially predict pCR to chemotherapy alone, enabling the avoidance of the unnecessary treatment of these patients with checkpoint inhibitors.<\/jats:p>","DOI":"10.3390\/jpm14050481","type":"journal-article","created":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T08:02:22Z","timestamp":1714723342000},"page":"481","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Immunologic Factors Associated with Differential Response to Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer"],"prefix":"10.3390","volume":"14","author":[{"given":"Robert J.","family":"Seager","sequence":"first","affiliation":[{"name":"Labcorp Oncology, Buffalo, NY 14263, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heidi","family":"Ko","sequence":"additional","affiliation":[{"name":"Labcorp Oncology, Durham, NC 27710, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarabjot","family":"Pabla","sequence":"additional","affiliation":[{"name":"Labcorp Oncology, Buffalo, NY 14263, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria-Fernanda","family":"Senosain","sequence":"additional","affiliation":[{"name":"Labcorp Oncology, Buffalo, NY 14263, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7025-3562","authenticated-orcid":false,"given":"Pawel","family":"Kalinski","sequence":"additional","affiliation":[{"name":"Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik","family":"Van Roey","sequence":"additional","affiliation":[{"name":"Labcorp Oncology, Buffalo, NY 14263, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuang","family":"Gao","sequence":"additional","affiliation":[{"name":"Labcorp Oncology, Buffalo, NY 14263, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyle C.","family":"Strickland","sequence":"additional","affiliation":[{"name":"Labcorp Oncology, Durham, NC 27710, USA"},{"name":"Department of Pathology, Duke University Medical Center, Duke Cancer Institute, Durham, NC 27710, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca Ann","family":"Previs","sequence":"additional","affiliation":[{"name":"Labcorp Oncology, Durham, NC 27710, USA"},{"name":"Department of Obstetrics & Gynecology, Duke University Medical Center, Duke Cancer Institute, Division of Gynecologic Oncology, Durham, NC 27710, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary K.","family":"Nesline","sequence":"additional","affiliation":[{"name":"Labcorp Oncology, Durham, NC 27710, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Hastings","sequence":"additional","affiliation":[{"name":"Labcorp Oncology, Durham, NC 27710, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shengle","family":"Zhang","sequence":"additional","affiliation":[{"name":"Labcorp Oncology, Buffalo, NY 14263, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey M.","family":"Conroy","sequence":"additional","affiliation":[{"name":"Labcorp Oncology, Buffalo, NY 14263, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taylor J.","family":"Jensen","sequence":"additional","affiliation":[{"name":"Labcorp Oncology, Durham, NC 27710, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcia","family":"Eisenberg","sequence":"additional","affiliation":[{"name":"Labcorp, Burlington, NC 27710, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Caveney","sequence":"additional","affiliation":[{"name":"Labcorp, Burlington, NC 27710, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric A.","family":"Severson","sequence":"additional","affiliation":[{"name":"Labcorp Oncology, Durham, NC 27710, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shakti","family":"Ramkissoon","sequence":"additional","affiliation":[{"name":"Labcorp Oncology, Durham, NC 27710, USA"},{"name":"Wake Forest Comprehensive Cancer Center and Department of Pathology, Wake Forest School of Medicine, Winston-Salem, NC 27710, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3506-0284","authenticated-orcid":false,"given":"Shipra","family":"Gandhi","sequence":"additional","affiliation":[{"name":"Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,4,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJMoa2112651","article-title":"Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer","volume":"386","author":"Schmid","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Gandhi, S. (2023). Novel Biomarkers to Guide Immunotherapy De-Escalation in the Neoadjuvant Setting in Triple-Negative Breast Cancer. J. Pers. Med., 13.","DOI":"10.3390\/jpm13091313"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1080\/14737140.2023.2265059","article-title":"The role of immune checkpoint inhibition in triple negative breast cancer","volume":"23","author":"Tarekegn","year":"2023","journal-title":"Expert Rev. Anticancer. Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1080\/13543784.2022.2008354","article-title":"Biomarkers for breast cancer immunotherapy: PD-L1, TILs, and beyond","volume":"31","author":"Rizzo","year":"2022","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"4024","DOI":"10.1007\/s00259-023-06394-y","article-title":"[18F]FDG PET\/CT for predicting triple-negative breast cancer outcomes after neoadjuvant chemotherapy with or without pembrolizumab","volume":"50","author":"Seban","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"6441","DOI":"10.1245\/s10434-023-13714-x","article-title":"Neoadjuvant Immunotherapy in Early, Triple-Negative Breast Cancers: Catching Up with the Rest","volume":"30","author":"Kim","year":"2023","journal-title":"Ann. Surg. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Iwase, T., Blenman, K.R.M., Li, X., Reisenbichler, E., Seitz, R., Hout, D., Nielsen, T.J., Schweitzer, B.L., Bailey, D.B., and Shen, Y. (2021). A Novel Immunomodulatory 27-Gene Signature to Predict Response to Neoadjuvant Immunochemotherapy for Primary Triple-Negative Breast Cancer. Cancers, 13.","DOI":"10.3390\/cancers13194839"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"5299","DOI":"10.1158\/1078-0432.CCR-21-0607","article-title":"Tumor-Specific Major Histocompatibility-II Expression Predicts Benefit to Anti-PD-1\/L1 Therapy in Patients with HER2-Negative Primary Breast Cancer","volume":"27","author":"Wulfkhule","year":"2021","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_9","first-page":"1","article-title":"Best Foot Forward: Neoadjuvant Systemic Therapy as Standard of Care in Triple-Negative and HER2-Positive Breast Cancer","volume":"40","author":"Sharma","year":"2020","journal-title":"Am. Soc. Clin. Oncol. Educ. Book Am. Soc. Clin. Oncol. Annu. Meet."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jmoldx.2017.10.001","article-title":"Analytical Validation of a Next-Generation Sequencing Assay to Monitor Immune Responses in Solid Tumors","volume":"20","author":"Conroy","year":"2018","journal-title":"J. Mol. Diagn. JMD"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Conroy, J.M., Pabla, S., Glenn, S.T., Seager, R.J., Van Roey, E., Gao, S., Burgher, B., Andreas, J., Giamo, V., and Mallon, M. (2021). A scalable high-throughput targeted next-generation sequencing assay for comprehensive genomic profiling of solid tumors. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0260089"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s40425-019-0506-3","article-title":"Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients","volume":"7","author":"Pabla","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1773200","DOI":"10.1080\/2162402X.2020.1773200","article-title":"Proliferative potential and response to nivolumab in clear cell renal cell carcinoma patients","volume":"9","author":"Zhang","year":"2020","journal-title":"Oncoimmunology"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Pabla, S., Seager, R.J., Van Roey, E., Gao, S., Hoefer, C., Nesline, M.K., DePietro, P., Burgher, B., Andreas, J., and Giamo, V. (2021). Integration of tumor inflammation, cell proliferation, and traditional biomarkers improves prediction of immunotherapy resistance and response. Biomark. Res., 9.","DOI":"10.1186\/s40364-021-00308-6"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.annonc.2022.02.004","article-title":"Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study","volume":"33","author":"Gianni","year":"2022","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1200\/JCO.2022.40.16_suppl.581","article-title":"Low TMB as predictor for additional benefit from neoadjuvant immune checkpoint inhibition in triple-negative breast cancer","volume":"40","author":"Karn","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/s41586-023-06498-3","article-title":"Spatial predictors of immunotherapy response in triple-negative breast cancer","volume":"621","author":"Wang","year":"2023","journal-title":"Nature"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"PD11-07","DOI":"10.1158\/1538-7445.SABCS22-PD11-07","article-title":"Association of TNBC-DX scores with outcomes in triple-negative breast cancer (TNBC) treated with neoadjuvant pembrolizumab and chemotherapy: A correlative analysis from NeoPACT and NeoSTOP trials","volume":"83","author":"Sharma","year":"2023","journal-title":"Cancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Wood, S.J., Gao, Y., Lee, J.H., Chen, J., Wang, Q., Meisel, J.L., and Li, X. (2024). High tumor infiltrating lymphocytes are significantly associated with pathological complete response in triple negative breast cancer treated with neoadjuvant KEYNOTE-522 chemoimmunotherapy. Breast Cancer Res. Treat.","DOI":"10.1007\/s10549-023-07233-2"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.molonc.2011.02.001","article-title":"The biology of cancer testis antigens: Putative function, regulation and therapeutic potential","volume":"5","author":"Fratta","year":"2011","journal-title":"Mol Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13048-018-0475-z","article-title":"Cancer-testis antigens in ovarian cancer: Implication for biomarkers and therapeutic targets","volume":"12","author":"Xie","year":"2019","journal-title":"J. Ovarian Res."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Nin, D.S., and Deng, L.W. (2023). Biology of Cancer-Testis Antigens and Their Therapeutic Implications in Cancer. Cells, 12.","DOI":"10.3390\/cells12060926"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"103223","DOI":"10.1016\/j.critrevonc.2021.103223","article-title":"Immunotherapy addition to neoadjuvant chemotherapy for early triple negative breast cancer: A systematic review and meta-analysis of randomized clinical trials","volume":"159","author":"Tarantino","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"034002","DOI":"10.1088\/2057-1739\/aa7e86","article-title":"Dynamic interplay between tumour, stroma and immune system can drive or prevent tumour progression","volume":"3","author":"Seager","year":"2017","journal-title":"Converg. Sci. Phys. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S1074-7613(00)00070-4","article-title":"Novel p19 Protein Engages IL-12p40 to Form a Cytokine, IL-23, with Biological Activities Similar as Well as Distinct from IL-12","volume":"13","author":"Oppmann","year":"2000","journal-title":"Immunity"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.bbrc.2012.11.006","article-title":"Regulation of cooperative function of the Il12b enhancer and promoter by the interferon regulatory factors 3 and 5","volume":"430","author":"Koshiba","year":"2013","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1146\/annurev.immunol.22.012703.104758","article-title":"Discovery and biology of IL-23 and IL-27: Related but functionally distinct regulators of inflammation","volume":"25","author":"Kastelein","year":"2007","journal-title":"Annu. Rev. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nri1001","article-title":"Interleukin-12 and the regulation of innate resistance and adaptive immunity","volume":"3","author":"Trinchieri","year":"2003","journal-title":"Nat. Rev. Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0065-2776(08)00605-6","article-title":"Emergence of the Th17 pathway and its role in host defense","volume":"99","author":"Palmer","year":"2008","journal-title":"Adv. Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1248\/yakushi.22-00150","article-title":"IFN-\u03b3 and IL-12 from Concentrated Ascites in Patients with Pancreatic Cancer Exerts Growth Inhibitory Effects against Pancreatic Cancer Cells","volume":"142","author":"Kobori","year":"2022","journal-title":"Yakugaku Zasshi"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1067\/mai.2003.1333","article-title":"IL-13 receptors and signaling pathways: An evolving web","volume":"111","author":"Hershey","year":"2003","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.immuni.2010.05.007","article-title":"Alternative Activation of Macrophages: Mechanism and Functions","volume":"32","author":"Gordon","year":"2010","journal-title":"Immunity"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"19589","DOI":"10.1038\/s41598-023-46237-2","article-title":"IL-4 and IL-13 induce equivalent expression of traditional M2 markers and modulation of reactive oxygen species in human macrophages","volume":"13","author":"Scott","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1067\/mai.2001.113759","article-title":"IgE regulation and roles in asthma pathogenesis","volume":"107","author":"Oettgen","year":"2001","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/08830189809084486","article-title":"Interleukin-4 and interleukin-13: Their similarities and discrepancies","volume":"17","author":"Chomarat","year":"1998","journal-title":"Int. Rev. Immunol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0167-5699(94)90021-3","article-title":"Interleukin 13, an interleukin 4-like cytokine that acts on monocytes and B cells, but not on T cells","volume":"15","author":"Zurawski","year":"1994","journal-title":"Immunol. Today"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Bommhardt, U., Schraven, B., and Simeoni, L. (2019). Beyond TCR Signaling: Emerging Functions of Lck in Cancer and Immunotherapy. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20143500"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S1074-7613(00)80184-3","article-title":"Lck activity controls CD4\/CD8 T cell lineage commitment","volume":"12","author":"Sohn","year":"2000","journal-title":"Immunity"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.immuni.2010.05.011","article-title":"Constitutively active Lck kinase in T cells drives antigen receptor signal transduction","volume":"32","author":"Nika","year":"2010","journal-title":"Immunity"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"7990","DOI":"10.1038\/sj.onc.1208074","article-title":"Function of the Src-family kinases, Lck and Fyn, in T-cell development and activation","volume":"23","author":"Palacios","year":"2004","journal-title":"Oncogene"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/humu.22523","article-title":"How the TP53 Family Proteins TP63 and TP73 Contribute to Tumorigenesis: Regulators and Effectors","volume":"35","author":"Candi","year":"2014","journal-title":"Hum. Mutat."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/19531","article-title":"p63 is a p53 homologue required for limb and epidermal morphogenesis","volume":"398","author":"Mills","year":"1999","journal-title":"Nature"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/19539","article-title":"p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development","volume":"398","author":"Yang","year":"1999","journal-title":"Nature"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/cdd.2011.181","article-title":"Regulation of skin aging and heart development by TAp63","volume":"19","author":"Paris","year":"2012","journal-title":"Cell Death Differ."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1038\/s41388-023-02859-4","article-title":"p63: A crucial player in epithelial stemness regulation","volume":"42","author":"Li","year":"2023","journal-title":"Oncogene"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/nrc861","article-title":"p73: Friend or foe in tumorigenesis","volume":"2","author":"Melino","year":"2002","journal-title":"Nat. Rev. Cancer."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1038\/cdd.2011.81","article-title":"p63 is a suppressor of tumorigenesis and metastasis interacting with mutant p53","volume":"18","author":"Melino","year":"2011","journal-title":"Cell Death Differ."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1158\/0008-5472.CAN-17-1803","article-title":"Distinct TP63 Isoform-Driven Transcriptional Signatures Predict Tumor Progression and Clinical Outcomes","volume":"78","author":"Abbas","year":"2018","journal-title":"Cancer Res."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Bankhead, A., McMaster, T., Wang, Y., Boonstra, P.S., and Palmbos, P.L. (2020). TP63 isoform expression is linked with distinct clinical outcomes in cancer. EBioMedicine, 51.","DOI":"10.1016\/j.ebiom.2019.11.022"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e007381","DOI":"10.1136\/jitc-2023-007381","article-title":"Systemic infusion of TLR3-ligand and IFN-\u03b1 in patients with breast cancer reprograms local tumor microenvironments for selective CTL influx","volume":"11","author":"Gandhi","year":"2023","journal-title":"J. Immunother. Cancer"}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/14\/5\/481\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:37:00Z","timestamp":1760107020000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/14\/5\/481"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,30]]},"references-count":50,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,5]]}},"alternative-id":["jpm14050481"],"URL":"https:\/\/doi.org\/10.3390\/jpm14050481","relation":{},"ISSN":["2075-4426"],"issn-type":[{"value":"2075-4426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,30]]}}}